Humanwell Healthcare (Group) Co. Ltd. has divulged Mas-related G-protein coupled receptor member X2 (MRGPRX2) antagonists reported to be useful for the treatment of pain, autoimmune disease and dermatological disorders.
Zhuhai Yufan Biotechnologies Co. Ltd. has identified molecular glue degraders comprising an E3 ubiquitin protein ligase-binding agent covalently bound to a DNA-binding protein Ikaros (IKZF1)-targeting moiety acting as IKZF1 degradation inducers potentially useful for the treatment of cancer, autoimmune disease, neurodegeneration and inflammatory disorders.
Vanderbilt University has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia and sleep disorders.
Researchers at Servizo Galego de Saude and Universidade de Santiago de Compostela have described senolytic compounds reported to be useful for the treatment of cancer, metabolic diseases, and neurological, dermatological, cardiovascular, eye, renal and inflammatory disorders.
Merck KGaA has synthesized transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) and/or TAZ/TEAD interaction inhibitors reported to be useful for the treatment of cancer.
Researchers at Ehime University, Hamamatsu University School of Medicine and Shizuoka University have disclosed compounds reported to be useful for the treatment of hepatitis C virus (HCV) infections.